Novo Nordisk A/S ADR (NVO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-1990 | 12-1989 | 12-1988 | 12-1987 | |
| Cash Flows From Operating Activities | ||||
| Net Income | 778,460 | 745,792 | 636,759 | 561,033 |
| Depreciation Amortization | 520,687 | 471,450 | 322,742 | 331,329 |
| Other Working Capital | 277,248 | -103,083 | 236,602 | 136,493 |
| Other Operating Activity | -61,959 | -115,315 | 55,543 | 23,586 |
| Operating Cash Flow | $1,514,436 | $998,844 | $1,251,646 | $1,052,441 |
| Cash Flows From Investing Activities | ||||
| PPE Investments | -1,235,032 | -978,563 | -746,396 | -908,178 |
| Other Investing Activity | 119,529 | -72,296 | -579,850 | 184,430 |
| Investing Cash Flow | $-1,115,503 | $-1,050,859 | $-1,326,246 | $-723,748 |
| Cash Flows From Financing Activities | ||||
| Dividend Paid | -125,505 | -116,508 | -101,905 | -122,475 |
| Other Financing Activity | -86,736 | 317,654 | 131,139 | 72,200 |
| Financing Cash Flow | $-212,241 | $201,146 | $29,234 | $-50,275 |
| Exchange Rate Effect | -36,750 | -10,284 | -62,474 | 5,320 |
| Beginning Cash Position | 489,631 | 360,784 | 436,938 | 260,082 |
| End Cash Position | 639,573 | 489,631 | 329,098 | 543,820 |
| Net Cash Flow | $149,942 | $128,847 | $-107,840 | $283,738 |
| Free Cash Flow | ||||
| Operating Cash Flow | 1,514,436 | 998,844 | 1,251,646 | 1,052,441 |
| Free Cash Flow | 1,514,436 | 998,844 | 1,251,646 | 1,052,441 |